Risperdal Lawsuit Trial Continues This Week Where A 20 Year Old Male Contends He Developed Gynecomastia (Enlarged Male Breasts) After Taking The Antipsychotic Drug To Treat Autism.
As the Risperdal bellwether trial continues in the Philadelphia Court of Common Pleas, Wright & Schulte LLC reports that a former U.S. Food and Drug Administration (FDA) commissioner testified Wednesday that Johnson & Johnson was aware as early as 2001 that Risperdal caused gynecomastia or excessive breast tissue in males. Bloomberg reported David Kessler, the former head of the FDA, testified that Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals, Inc., funded a study in 2001 that found nearly 3.8 percent of boys who took Risperdal during a clinical trial developed breasts that were either “probably or very likely” caused by the medication. The Risperdal lawsuit trial, which began on January 23, involves a lawsuit filed on behalf of a 20-year-old Alabama man who used the medication for autism when he was 8 years old. According to the Risperdal complaint, the plaintiff allegedly experienced weight gain and gynecomastia due to using the Risperdal antipsychotic drug. The Risperdal lawsuit accuses Johnson & Johnson and Janssen of improperly marketing Risperdal to boys without disclosing the side-effects associated with the medication. (Case No. 1204-01997; In Re: Risperdal Litigation, Case Number 100300296)
[bloomberg.com/news/articles/2015-01-28/j-j-knew-drug-could-cause-breasts-in-boys-ex-fda-official-says, January 28, 2015]
The attorneys at Wright & Schulte LLC continues to speak with men who believe they have experienced side-effects from Risperdal and other antipsychotic drugs and offers free legal consultations. To speak with one of the firm’s experienced drug lawyers, call 1-800-399-0795 or visit www.yourlegalhelp.com for more information on this and other drug side-effects.
Risperdal Lawsuit Trial
The Risperdal complaint centered in this Risperdal lawsuit trial is representative of Risperdal lawsuits consolidated in the Philadelphia Court of Common Pleas’ mass tort program. The complaints are brought on behalf of males who allege that they developed female-like breasts, diabetes, gained weight and suffered other side-effects as a result of taking Risperdal antipsychotic medication. Due to the growing number of Risperdal lawsuit filings which have common questions of fact and allegations, the Pennsylvania state court consolidated the complaints for pretrial proceedings. The court’s master case list shows 1,266 Risperdal cases are pending as of February 2. According to the court’s docket, other Risperdal bellwether trials are scheduled for February 17, March 16 and March 30. (In Re: Risperdal Litigation, Case Number 100300296)
Risperdal (risperidone) is an atypical antipsychotic drug approved by the FDA to treat adult and children with schizophrenia and bipolar disorder and irritability in autistic children. Among the Risperdal side-effects is gynecomastia, which is abnormal male breast growth. The growth occurs since Risperdal elevates the levels of the female hormone, prolactin, according to prescribing information for Risperdal. The elevation of prolactin persists the longer the medication is taken. Risperdal is associated with higher levels of prolactin elevation than other antipsychotic agents, according to the drug’s prescribing information. The FDA ordered a black-box warning, the agency’s most serious warning, to note that Risperdal is not approved by the FDA for use in elderly patients with dementia-related psychosis.
[accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf, June 2009]
Bloomberg reported that during cross-examination at the bellwether trial, Johnson & Johnson’s lawyers called David Kessler, a “biased witness” since he has testified in other trials that drug manufacturers conceal the risks associated with their medications. The company’s lawyers accused the former FDA commissioner of “cutting and pasting” findings from other cases to arrive at his conclusion that Janssen knew Risperdal caused gynecomastia in some boys but did not disclose the information to doctors and their patients and government regulators. Bloomberg further reported that Risperdal was once a top-selling drug for Johnson & Johnson with $24.2 billion in global sales from 2003 to 2010. Sales decreased after Johnson & Johnson lost its patent protection.
[bloomberg.com/news/articles/2015-01-30/j-j-attacks-ex-fda-chief-in-male-breast-growth-case-over-drug, January 30, 2015]
About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Risperdal lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.
Wright & Schulte LLC
865 S. Dixie Dr.
Vandalia, Ohio 45377